万达生物制药公司近日对其药物Bysanti的使用说明进行了重要更新，新增了一项安全警告。该警告指出，在患有痴呆相关精神病的老年患者群体中，使用Bysanti可能导致死亡率增加。
这一更新是基于最新的临床数据和安全性评估结果。公司强调，医疗专业人员在为这类特定患者群体处方Bysanti时，需仔细权衡其获益与潜在风险。
万达生物制药公司近日对其药物Bysanti的使用说明进行了重要更新，新增了一项安全警告。该警告指出，在患有痴呆相关精神病的老年患者群体中，使用Bysanti可能导致死亡率增加。
这一更新是基于最新的临床数据和安全性评估结果。公司强调，医疗专业人员在为这类特定患者群体处方Bysanti时，需仔细权衡其获益与潜在风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.